Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03394716 : Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors
Phase
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Primary brain tumor (WHO IV, GBM); treated with fractionated radiotherapy with or
without preceding surgery. Systemic treatment is allowed before and during
radiotherapy.

- Brain metastasis (from a solid extracranial tumor) eligible for treatment with
fractionated radiotherapy with or without preceding surgery. Systemic treatment is
allowed before and during radiotherapy.

Also, postoperative patients with a macroscopic residual tumor lesion can be included (the
diagnosis of residual diseases is defined by the treating neurosurgeon or on the MRI
executed within 24 hours after the surgery, the diagnosis of residual macroscopic disease
should always be confirmed during the neuro-oncology multidisciplinary meeting).

Exclusion Criteria:

- Patients receiving Whole Brain RT (WBRT)

- Patient with a poor kidney function (GFR < 30 mL/min; CKD 4 and 5; patients on
dialysis and patients with acute kidney insufficiency)

- None, doubtful or very small (<5 mm in its largest dimension) contrast enhancing
lesion

- Patients with a contraindication for MRI
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03394716      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740